Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026
Rhea-AI Summary
Edgewise Therapeutics (Nasdaq:EWTX) announced that company leadership will present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026, at 10:00 am ET.
The presentation will be available via live webcast through the Edgewise Events & Presentations page and will remain accessible for replay for a limited time.
Positive
- None.
Negative
- None.
News Market Reaction – EWTX
In the May 12 session, EWTX declined 1.59%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 2026 earnings | Neutral | -3.8% | Quarterly results and pipeline updates in muscular dystrophy and cardiovascular programs. |
| May 04 | Inducement grants | Neutral | +2.7% | Stock option inducement grants to new non-executive employees under 2024 plan. |
| Apr 01 | Inducement grants | Neutral | +5.2% | Additional inducement stock options granted to new non-executive employees. |
| Mar 10 | Clinical data update | Positive | +2.2% | Positive long-term sevasemten data in Becker muscular dystrophy with sustained stabilization. |
| Mar 04 | Conference presentation | Neutral | +0.2% | Announcement of Leerink Global Healthcare Conference presentation and webcast access details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News about conferences and corporate updates has generally seen modest to positive reactions, while earnings drew a negative move.
Over the past few months, Edgewise reported Q1 2026 results with a net loss of $49.0M and highlighted upcoming readouts. Inducement option grants were disclosed on May 4 and April 1, 2026, each tied to small positive price moves. In March, the company released positive long-term sevasemten Becker muscular dystrophy data and announced a Leerink conference presentation on March 11, 2026, both followed by mild gains. Today’s RBC conference appearance fits this pattern of regular investor engagement updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay for a limited time following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of symptomatic hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to edgewisetx.com or follow us on LinkedIn and X.
View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference-on-may-20-2026-302768502.html
SOURCE Edgewise Therapeutics